Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...

Researchers performed a retrospective chart review and survey of 107 patients to compare the efficacy, patient satisfaction, cost and known adverse effects of denosumab versus zoledronic acid, ...

Abxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: AMRX), today announced that the U.S.

Amneal Pharma receives US FDA approval for denosumab biosimilars Prolia and Xgeva: Bridgewater, New Jersey Friday, December 26, 2025, 16:00 Hrs [IST] Bridgewater headquartered Amn ...

A similar adverse event (AE) profile was observed in the EVENITY groups, regardless of prior treatment group (placebo or denosumab). In patients treated with EVENITY for months 36 to 48, serious AEs ...

LOS ANGELES, May 28 (Reuters) - Amgen Inc said on Wednesday its experimental osteoporosis drug denosumab achieved greater bone density than Merck & Co Inc's Fosamax, but some analysts expressed ...

Stoboclo and Osenvelt, biosimilars of Prolia and Xgeva, are approved for various cancer-related bone conditions, offering cost-effective alternatives. FDA approval confirms therapeutic equivalence of ...

"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...

LOS ANGELES, Dec 14 (Reuters) - Amgen Inc said on Friday that osteoporosis drug denosumab, the biotechnology company's most important new offering, increased bone strength in women receiving hormone ...

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...